UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Interventional pharmacoeconomics for immune checkpoint inhibitors through alternative dosing strategies

British journal of cancer, 2023-10, Vol.129 (9), p.1389-1396

2023

Volltextzugriff (PDF)

Sorafenib Is an Inhibitor of UGT1A1 but Is Metabolized by UGT1A9: Implications of Genetic Variants on Pharmacokinetics and Hyperbilirubinemia

Clinical cancer research, 2012-04, Vol.18 (7), p.2099-2107

2012

Volltextzugriff (PDF)

Metastasis-Specific Gene Expression in Autochthonous and Allograft Mouse Mammary Tumor Models: Stratification and Identification of Targetable Signatures

Molecular cancer research, 2020-09, Vol.18 (9), p.1278-1289

2020

Volltextzugriff (PDF)

Low serum mesothelin in pancreatic cancer patients results from retention of shed mesothelin in the tumor microenvironment

Translational oncology, 2022-07, Vol.21, p.101440-101440, Article 101440

2022

Volltextzugriff (PDF)

Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancers

Frontiers in oncology, 2024, Vol.14, p.1386190-1386190

2024

Volltextzugriff (PDF)

Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors

Journal for immunotherapy of cancer, 2021-11, Vol.9 (11), p.e003388

2021

Volltextzugriff (PDF)

Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma

Blood cancer journal (New York), 2024-09, Vol.14 (1), p.164-5, Article 164

2024

Volltextzugriff (PDF)

Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer

Journal of clinical oncology, 2018-05, Vol.36 (14), p.1389-1395

2018

Volltextzugriff (PDF)

Pharmacokinetics and tolerability of the dual TORC1/2 inhibitor sapanisertib in combination with the MEK inhibitor trametinib in dogs

Frontiers in veterinary science, 2022-12, Vol.9, p.1056408-1056408

2022

Volltextzugriff (PDF)

A Quantitative Pharmacology Model of Exosome-Mediated Drug Efflux and Perturbation-Induced Synergy

Pharmaceutics, 2021-06, Vol.13 (7), p.997

2021

Volltextzugriff (PDF)

Selumetinib in Children with Inoperable Plexiform Neurofibromas

The New England journal of medicine, 2020-04, Vol.382 (15), p.1430-1442

2020

Volltextzugriff (PDF)

Systemic immune changes accompany combination treatment with immunotoxin LMB‐100 and nab‐paclitaxel

Cancer medicine (Malden, MA), 2023-02, Vol.12 (4), p.4236-4249

2023

Volltextzugriff (PDF)

Pulmonary tumor thrombotic microangiopathy and pulmonary veno-occlusive disease in a woman with cervical cancer treated with cediranib and durvalumab

BMC pulmonary medicine, 2018-07, Vol.18 (1), p.112-112, Article 112

2018

Volltextzugriff (PDF)

Pharmacokinetics of Pomalidomide in a Patient Receiving Hemodialysis Using a High-Cutoff Filter

American journal of kidney diseases, 2017-04, Vol.69 (4), p.553-554

2017

Volltextzugriff (PDF)

PARP inhibitors: A review of the pharmacology, pharmacokinetics, and pharmacogenetics

Seminars in oncology, 2024-02, Vol.51 (1-2), p.19-24

2024

Volltextzugriff (PDF)

Development and utilization of a combined LC–UV and LC–MS/MS method for the simultaneous analysis of tegafur and 5-fluorouracil in human plasma to support a phase I clinical study of oral UFT®/leucovorin

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2012-06, Vol.898, p.32-37

2012

Volltextzugriff (PDF)

First‐in‐Human Phase I Study of Envafolimab, a Novel Subcutaneous Single‐Domain Anti‐PD‐L1 Antibody, in Patients with Advanced Solid Tumors

The oncologist (Dayton, Ohio), 2021-09, Vol.26 (9), p.e1514-e1525

2021

Volltextzugriff (PDF)

Ibrutinib's off-target mechanism: cause for dose optimization

Cancer biology & therapy, 2021-12, Vol.22 (10-12), p.529-531

2021

Volltextzugriff (PDF)

Dose Optimization of Pembrolizumab: Less May Be More

Clinical pharmacology and therapeutics, 2022-05, Vol.111 (5), p.993-993

2022

Volltextzugriff (PDF)

IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset Expansion

Clinical cancer research, 2019-08, Vol.25 (16), p.4945-4954

2019

Volltextzugriff (PDF)

Development and validation of a simple, selective, and sensitive LC-MS/MS assay for the quantification of remdesivir in human plasma

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2021-05, Vol.1171, p.122641-122641, Article 122641

2021

Volltextzugriff (PDF)

Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose Deescalation

Journal of clinical pharmacology, 2022-04, Vol.62 (4), p.532-540

2022

Volltextzugriff (PDF)

1 – 25 von 167

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieBlood

ThemaAnimals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(162)
Mit Volltextzugriff
(151)

Publikationsform

Sprache

Englisch
(167)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Interventional pharmacoeconomics for immune checkpoint inhibitors through alternative dosing strategies

Sorafenib Is an Inhibitor of UGT1A1 but Is Metabolized by UGT1A9: Implications of Genetic Variants on Pharmacokinetics and Hyperbilirubinemia

Metastasis-Specific Gene Expression in Autochthonous and Allograft Mouse Mammary Tumor Models: Stratification and Identification of Targetable Signatures

Low serum mesothelin in pancreatic cancer patients results from retention of shed mesothelin in the tumor microenvironment

Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancers

Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors

Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma

Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer

Pharmacokinetics and tolerability of the dual TORC1/2 inhibitor sapanisertib in combination with the MEK inhibitor trametinib in dogs

A Quantitative Pharmacology Model of Exosome-Mediated Drug Efflux and Perturbation-Induced Synergy

Selumetinib in Children with Inoperable Plexiform Neurofibromas

Systemic immune changes accompany combination treatment with immunotoxin LMB‐100 and nab‐paclitaxel

Pulmonary tumor thrombotic microangiopathy and pulmonary veno-occlusive disease in a woman with cervical cancer treated with cediranib and durvalumab

Pharmacokinetics of Pomalidomide in a Patient Receiving Hemodialysis Using a High-Cutoff Filter

PARP inhibitors: A review of the pharmacology, pharmacokinetics, and pharmacogenetics

Development and utilization of a combined LC–UV and LC–MS/MS method for the simultaneous analysis of tegafur and 5-fluorouracil in human plasma to support a phase I clinical study of oral UFT®/leucovorin

Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study

First‐in‐Human Phase I Study of Envafolimab, a Novel Subcutaneous Single‐Domain Anti‐PD‐L1 Antibody, in Patients with Advanced Solid Tumors

Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress

Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer

Ibrutinib's off-target mechanism: cause for dose optimization

Dose Optimization of Pembrolizumab: Less May Be More

IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset Expansion

Development and validation of a simple, selective, and sensitive LC-MS/MS assay for the quantification of remdesivir in human plasma

Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose Deescalation

Aktive Filter

Suchergebnisse filtern